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ABSTRACT 
Epidemiological data indicate that patients who experience a traumatic brain injury (TBI) 
have an elevated risk of developing a substance use disorder (SUD), but the underlying 
neurobiological connections remain unclear. To further understand the relationship between TBI 
and SUD, we investigated the effects of TBI on the abuse-related effects of oxycodone in 
preclinical models. Our evaluation utilized a lateral fluid percussion injury of moderate severity in 
adult male Sprague-Dawley rats. In the first aim, we tested the hypothesis that moderate TBI 
increases the risk for relapse to an opioid use disorder as measured by reinstatement of lever-
pressing behavior following extinction in an intravenous oxycodone self-administration procedure. 
In the second aim, we tested the hypothesis that moderate TBI increases physiological dependence 
to oxycodone as measured by decreases in food-reinforced lever-pressing behavior and increases 
in other withdrawal behaviors in both precipitated withdrawal and spontaneous withdrawal. In 
tests for self-administration, brain-injured subjects, relative to non-injured subjects, showed no 
significant differences in the number of oxycodone-reinforced sessions required to meet stable 
maintenance criteria for lever-pressing behavior. Likewise, brain-injured subjects showed no 
significant differences in the number of non-reinforced sessions to meet extinction criteria for 
lever-pressing behavior relative to non-injured subjects. In tests for reinstatement, non-injured 
subjects reinstated responding under oxycodone-associated cue- and oxycodone prime-induced 
conditions, however, brain-injured subjects did not reinstate lever-pressing behavior under any 
conditions. In tests for physical dependence, brain-injured subjects showed no significant 
differences from non-injured subjects with regards to their mean withdrawal scores or food-
reinforced lever-pressing behavior. Overall, these data suggest that brain-injured patients no 
significant pre-morbid history of opioid abuse are at a lesser risk of relapse to opioid use disorders. 
Moreover, the characteristic withdrawal syndrome in opioid-dependent patients may not 
contribute to continued opioid abuse to a greater degree in brain-injured patients than compared to 
non-injured patients.  
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CHAPTER 1: INTRODUCTION 
Substance abuse is a major public health concern that imposes a broad range of costs on 
society.  The Diagnostic and Statistical Manual of Mental Disorders (DSM) characterizes 
substance abuse as “a maladaptive pattern of substance use manifested by recurrent and significant 
adverse consequences related to the repeated use of substances” [1]. In the earliest human records, 
psychoactive substances were used by priests for religious ceremonies, healers for medicinal 
purposes, and by the general population in a variety of ways [2]. Today, regular drug use may 
evolve into a problem of drug abuse that taxes our healthcare system and results in lost workplace 
productivity and accidental hazards. In 2004, the World Health Organization estimated that at least 
15.3 million people worldwide have drug use disorders and in 2007, the United States National 
Drug Intelligence Center estimated that the total economic costs of substance abuse exceeded 193 
billion dollars annually [3,4]. In 2013, the National Survey on Drug Use and Health estimated that 
21.6 million Americans aged 12 or older abused illicit drugs in the past year based on the DSM 
criteria for substance abuse [5]. A recent report by the National Institute of Health Office of Budget 
indicated that the research awards supported by the National Institute on Drug Abuse for the fiscal 
year of 2014 totaled nearly 770 million dollars [6]. Substance abuse and dependence are well-
recognized public health problems and remain of great interest to researchers and research 
institutions alike.  
Over the past century, substance abuse research has produced various therapeutics that aid 
the cessation of substance abuse, but those treatments are not always efficacious and are not 
without side-effects. Relapse to substance abuse remains a possibility even after successful 
treatment or sustained abstinence. Withdrawal symptoms can persist at low intensities for days, 
weeks, or months depending on the particular drug and doses at which the user became dependent. 
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In this case, resumption of substance abuse behaviors serves to alleviate the persistent withdrawal 
dysphoria. In addition, limited periods of controlled, non-problematic drug use can lead to rapid 
escalation in consumption after abstinence. In 2004, the National Survey on Drug Use and Health 
reported that only 3.8 million Americans of the 22.5 million Americans that were classified with 
substance dependence received treatment in that year [5]. Research in the abuse of substances has 
yielded numerous advances in our understanding of relapse to substance abuse, however, it 
remains a considerable public health issue that requires additional research to adequately address.  
Of interest to drug abuse researchers is the relationship between traumatic brain injury (TBI) and 
substance use disorders (SUD). In 2006, the National Center for Injury Prevention and Control 
estimated that 1.7 million people in the United States sustain a TBI each year, of which 275,000 
are hospitalized and 1.365 million are released from an emergency department [7]. Similar 
estimates by the National Institutes of Health in 1998 indicated that 70,000 to 90,000 individuals 
that experience a TBI suffer from substantial long-term loss of physical, cognitive, emotional, and 
behavioral function [8]. At present, the relationship between TBI and SUD has been investigated 
almost entirely from the perspective of drug intoxication as the cause of trauma [9]. It has been 
well-established that drug intoxication itself increases the risk of TBI and that the chief causes of 
that trauma include motor vehicle accidents, falls, or involvement in acts of violence [10,11].  
Clinical evidence has emerged, however, of a correlation between the incidence of TBI and 
SUD in patients that have no history of significant substance use prior to injury.  In a 2000 study, 
it was reported that the relative risk of substance abuse in patients with TBI (22%) was 1.3 fold 
greater than the risk of substance abuse in patients without TBI (16.7%) [12].  In a 2004 study of 
188 TBI patients of whom 70 percent did not self-report substance abuse pre-injury, the prevalence 
of substance abuse rose from 14 percent at 1-year post-injury to 17 percent 3-years post-injury 
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[13]. A 2004 study reported that TBI patients with no evidence of mental illness or substance 
abuse-related service utilization in the year prior to injury had a 4.5 odds ratio of substance abuse 
within the first year post-injury and still had a 1.4 times greater risk when evaluated at 25-36 
months post injury [14].  
Overall, epidemiological data support a connection between experiencing a TBI and 
developing a SUD. It is unclear, however, if the correlation between TBI and SUD reflects a coping 
mechanism or if neuroanatomical and neurochemical changes induced by brain injury result in 
increased vulnerability to development of substance use disorders. At the inception of this project, 
the manifestation of SUD as a result of TBI had yet to be investigated in preclinical models [9]. 
Currently, there is only one published study on the effects of TBI in a preclinical model of self-
administration, more specifically a rodent model of ethanol self-administration where changes in 
ethanol intake in ethanol experienced subjects were assessed before and after TBI  [15]. However, 
no research has been published regarding the TBI-induced changes in intake of any other abused 
substance in drug naïve or drug experienced subjects. 
Since bodily trauma is often comorbid with TBI, clinical management of pain with opioid 
analgesics is common in TBI patients. It follows, then, that TBI patients are likely to be exposed 
to opioid analgesics during the course of their medical care. Over the last decade, as prescription 
opioid sales sharply increased, rates of prescription opioid abuse have also continued to rise, and 
as a result treatment admissions and deaths due to overdose are at epidemic levels [16,17]. 
Mortality rates due to opioid-analgesic poisonings nearly quadrupled in the years between 1999 
and 2011, and in 2011 alone there were 41,340 deaths due to drug poisoning, 41% (16,917 deaths) 
of them involved opioid analgesics [18]. In cases of prescription opioid abuse that do not result in 
death, continued abuse of medication is common. In cases of prescription opioid abuse where 
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abstinence is an outcome, relapse remains a possibility [19]. Moreover, repeated use of pain 
medication is likely to lead to the development of physical dependence [20] and withdrawal-
induced dysphoria after abrupt cessation of opioid intake may contribute to continued drug taking 
[21].  
Given the greater incidence of substance abuse in brain-injured patients and high 
probability of exposure to opioids prescribed in the course of treatment following brain injury, we 
investigated the effects of TBI on the response to oxycodone in preclinical models of abuse-related 
behaviors in rats. In the first aim, we tested the hypothesis that moderate TBI increases the risk for 
relapse to an opioid use disorder as measured by reinstatement of lever-pressing behavior 
following extinction in an intravenous oxycodone self-administration procedure. In the second 
aim, we tested the hypothesis that moderate TBI increases physiological dependence to oxycodone 
as measured by decreases in food-reinforced lever-pressing behavior and increases in other 
withdrawal behaviors in both precipitated withdrawal and spontaneous withdrawal.  
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CHAPTER 2: PART 1 
2.1 OVERVIEW OF CLASSICAL CONDITIONING 
In 1927, Ivan Pavlov published a report titled Conditioned Reflexes, An Investigation of 
the Physiological Activity of the Cerebral Cortex. Pavlov systematically investigated the 
adjustments organisms make in response to the presentation of various environmental and 
proprioceptive stimuli [22]. In a typical Pavlovian experiment, a neutral stimulus (NS), which 
initially elicits no physiological response, is repeatedly paired with the presentation of an 
unconditional stimulus (US), a stimulus that alone is capable of eliciting a physiological response 
termed the unconditioned response (UR). Organisms learn to associate the NS with the US, and 
after several couplings, the NS alone can trigger a response that is similar to the response triggered 
by the US, known as the conditioned response (CR). At this point, the NS is no longer neutral 
since it has gained the ability to elicit a physiological response and is now referred to as the 
conditional stimulus (CS). In Pavlov’s experiments, dogs were conditioned to salivate (CR) upon 
presentation of a tone (CS) after repeated pairing with food powder (US). In the case of drug-
related behaviors, a NS is predictably followed by a US, the effects of the drug. As a result of 
repeated pairings, the CS elicits a CR which is similar to that of the UR, or the drug effects. 
Conditioned cues that are present during drug administration serve as conditioned reinforcers of 
drug-seeking behaviors if the effects of the drug are positively reinforcing [23]. 
In 1935, Clark Hull expanded on the understanding of Pavlov’s experiments by introducing 
the drive reduction theory. Motivation, Hull proposed, has both drive and incentive components. 
He states, “the incentive is that substance or commodity in the environment which satisfies a need, 
i.e., which reduces a drive” [24]. In 1948, Abraham Wikler applied Hull’s theory to the 
phenomenon of substance abuse relapse. He proposed that through a process of associative 
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learning, neutral stimuli in the environment can, over the course of many pairings with drug taking, 
come to elicit conditioned withdrawal responses in drug dependent subjects [25]. For example, if 
the sight of a needle, syringe, or white powder (NS) is repeatedly paired with a diminishing drug 
level (UR) during withdrawal (US), those cues may then serve as conditional stimuli (CS), which 
elicit a conditioned withdrawal response (CR). If the conditioned cues are presented after a period 
of abstinence from substance abuse, the subject’s desire to relieve the conditioned dysphoria may 
result in a relapse to drug consumption [26,27] 
2.2 OVERVIEW OF OPERANT CONDITIONING 
Over the last several decades, animal models have been used extensively to investigate the 
neurobiological and behavioral mechanisms underlying vulnerability to relapse. A “reinstatement 
model” allows researchers to analyze drug-seeking and relapse-like behavior. Many experimental 
models in substance abuse research, including the reinstatement model as it is used in self-
administration, are fundamentally dependent on the principles of operant conditioning.  
 In 1930, Burrhus Skinner first described the use of operant chambers to study animal 
behavior in a paper titled On the Conditions of Elicitation of Certain Eating Reflexes [28–30]. In 
1938, Skinner published The Behavior of Organisms which set forth the principles for the 
experimental analyses that we perform today. In a typical Skinnerian experiment, organisms adjust 
their behavior according to the behavior-consequence contingencies specified by the investigators. 
If a consequence increases the probability of the behavior antecedent to it, it is termed a reinforcer. 
If a consequence decreases the probability of a behavior antecedent to it, it is termed a punisher. 
If a reinforcing or punishing stimulus is presented it is termed positive, however, if it is removed 
from the system it is termed negative. The relationship between the behaviors and their 
consequences is referred to as a two-term contingency. If for any two-term contingency, the 
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probability of emission of the behavior is increased or decreased only in the presence of a given 
stimulus, it is known as a three-term contingency and the modulating stimulus is known as 
discriminative stimulus [31]. For example, a light in an illuminated state may signal that the 
emission of a lever press behavior will consequently be followed by the presentation of a food 
pellet, however, when the light is not illuminated the contingency does not apply. In this regard, 
the illuminated light serves as the discriminative stimulus and the presentation of the food pellet 
is a form of positive reinforcement since the stimulus is added to the system and increases the 
probability of the behavior antecedent to it. In these experiments, the effect of a specified 
consequence on a particular behavior can be evaluated by measuring the total number of emitted 
behaviors or the rate of the emission of those behaviors.  
It is also possible to manipulate the way a reinforcer is delivered as a function of responding 
to investigate the ways in which organisms adjust to consequences of their behaviors. In operant 
conditioning, reinforcement schedules commonly consist of ratio schedules and interval schedules. 
In ratio schedules, a specified number of behaviors must be emitted for the delivery of 
reinforcement. For example, in a fixed ratio schedule (FR) the number of required responses is 
fixed whereas in a variable ratio schedule (VR), the number of required responses varies around 
a mean of the ratio of the schedule. In interval schedules, a specified amount of time must elapse 
after the last reinforced behavior before subsequent behaviors are reinforced. For example, in a 
fixed interval schedule (FI) the amount of time that must elapse is fixed whereas in a variable 
interval schedule (VR) the amount of time that must elapse varies around a mean of the interval 
of the schedule [32]. Schedules of reinforcement are frequently manipulated in the case of self-
administration procedures and reinstatement procedures as discussed in the subsequent sections.  
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2.3 ORIGINS OF THE SELF-ADMINISTRATION PROCEDURE 
In 1940, Sidney Spragg published a monograph titled Morphine Addiction in Chimpanzees.  
Spragg applied Hull’s drive reduction theory to chimpanzees. In an experimental room separate 
from their living quarters, chimpanzees were administered morphine injections twice daily for an 
average four weeks or until they were opioid-dependent. Given a choice between food and drug, 
chimpanzees preferred the injection to food when experiencing withdrawal symptoms. Spragg’s 
results suggest that relief of morphine-induced withdrawal symptoms may serve as sufficient 
reinforcement for the development of drug-seeking behavior and that the positive drug effects 
serve as conditioned reinforcers as later suggested by Wikler [25,33]. 
  In 1957, Horace Beach published a report titled Morphine Addiction in Rats in which he 
used a Y-choice discrimination box to determine whether rats would seek stimuli associated with 
the drugs effects [34]. After habituation to the apparatus, subjects were given the choice of two 
distinctly different contexts with unique cues (goal boxes). After baseline preference 
determination, rats were administered morphine or saline injections once daily for twelve days and 
then immediately placed in either their preferred or non-preferred goal box. Given a choice 
between stimuli previously associated with the drug effects and stimuli not previously associated 
with the drug effects, rats showed a significant preference for the stimuli previously associated 
with drug effects as compared to their baseline preference.   As suggested by Spragg in 1940 and 
Wikler in 1948, Beach’s results support the hypothesis that both the euphoric effects of morphine 
and the action of morphine in relieving withdrawal distress are sufficiently reinforcing to promote 
the development of morphine-seeking behavior. 
In 1962, James Weeks published a paper in Science titled Experimental Morphine 
Addiction: Method for Automatic Intravenous Injections in Unrestrained Rats, which laid the 
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foundation for the self-administration procedures that are widely used in substance abuse research 
today. Weeks surgically implanted polyethylene cannulae into the jugular veins of albino female 
rats using a technique developed by Vojin Popovic [35]. With the ability to directly introduce 
morphine sulfate to the rodent circulatory system, Weeks applied Skinner’s (1938) fundamental 
principles of operant conditioning to study the effect of drugs on animal behavior. In operant 
boxes, relatively unrestrained rodents could then utilize a self-injection technique to intravenously 
administer morphine sulfate by lever press activation of an automatic syringe driver. It was shown 
that the rate of self-administration of morphine varied inversely by the dose. It was also shown 
that morphine acted as a reinforcer that produced almost immediate relief from withdrawal in 
dependent subjects as shown previously by Spragg (1940) in chimpanzees and Beach (1957) in 
rats [36]. 
2.4 ORIGINS OF THE REINSTATEMENT PARADIGM 
Substance abuse relapse is studied in animal models of reinstatement which often utilize 
self-administration procedures. In a typical self-administration experiment with a reinstatement 
design, subjects learn to press a lever in an operant chamber for an intravenous infusion of drug 
during the acquisition phase. Once the subjects reliably press a lever for drug infusion, and stable 
drug-taking behavior is reproducible, the subjects are considered to be in the maintenance phase. 
It is then possible to extinguish the learned contingency by replacing the drug infusion with a saline 
infusion or no infusion, of which the latter two do not serve as reinforcing stimuli when presented. 
Often this results in an extinction burst which is characterized by a sudden and temporary increase 
in the subject’s response frequency.  Once subjects learn that the reinforcement is no longer a 
consequence of lever-pressing behavior, they are considered to be in the extinction phase. A non-
contingent, pre-session drug injection, referred to as a drug priming, may renew the previously 
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extinguished expression of lever-pressing behavior, even when the emission of that behavior does 
not result in drug infusion. A drug priming model is designed to simulate an exposure to the drug 
that was abused or a related drug after treatment or abstinence in humans.  Similarly, an 
exteroceptive cue, or cue priming and a noxious stimulus or stress priming will also result in the 
renewed expression of previously extinguished lever pressing behavior. A cue priming model is 
designed to simulate exposure to drug-associated cues, such as drug paraphernalia, that can lead 
to renewed drug taking. A stress priming model is designed to simulate renewed drug taking in 
response to major life stressors such as grief, sorrow, and anger. 
In 1971, Rodger Stretch, Gary Gerber, and Susan Wood published a study titled Factors 
Affecting Behavior Maintained by Response-Contingent Intravenous Infusions in Squirrel 
Monkeys which utilized such a procedure. In daily two hour sessions, subjects developed drug-
seeking behavior for intravenous infusions of d-amphetamine on a modified progressive ratio 
schedule of reinforcement. Responding was then extinguished by replacing infusions of d-
amphetamine with infusions of saline. When pre-session intramuscular injections of d-
amphetamine were administered, responding was restored and indistinguishable from that 
observed when drug infusions were available [37]. Researchers later termed this phenomenon 
prime-induced reinstatement.  
In 1976, Marvin Davis and Stanley Smith, using a self-administration procedure, explored 
the motivational properties of secondary reinforcers derived from the primary reinforcing effects 
of intravenous morphine injections. Subjects were trained to acquire morphine self-administration 
with a buzzer presentation during each morphine infusion. By substituting saline for morphine, the 
lever press behavior was extinguished in the absence of the buzzer, the reinforcing conditioned 
stimulus. In subsequent sessions, elevated responding occurred during the presentation of the 
  
14 
buzzer, confirming the occurrence of secondary reinforcement [38]. Researchers later termed this 
phenomenon cue-induced reinstatement.  
In 1995, Yavin Shaham and Jane Stewart tested the effect of footshock stress on relapse to 
heroin-seeking behavior. Subjects trained on intravenous heroin self-administration were exposed 
to footshock stress in a reinstatement procedure after extinction. After numerous extinction 
sessions, and after a prolonged drug-free period, the footshock stress produced responding that 
mimicked the effect of a non-contingent priming infusion of heroin. Such results suggest that stress 
is a powerful stimulus for relapse to drug-seeking behavior and is comparable to heroin itself [39]. 
Researchers later termed this phenomenon stress-induced reinstatement.  
In summary, these three approaches are commonly utilized to reinstate drug-taking 
behavior in preclinical models. A non-contingent, pre-session drug injection, referred to as a drug-
priming; presentation of an exteroceptive cue, or cue priming and a noxious stimulus or stress 
priming have all been repeatedly demonstrated to renew expression of extinguished lever pressing 
behavior even when the emission of that behavior does not result in drug infusion. Overall, the 
individual approaches to inducing reinstatement in preclinical models have provided information 
about the underlying neuroanatomical circuitry and neurochemical mechanisms that drive relapse 
in humans.   
2.5 CURRENT UNDERSTANDING OF REINSTATEMENT TO OPIOID SELF-
ADMINISTRATION 
A database search for published literature on reinstatement of opioid self-administration 
yields a number of preclinical studies in which agonists and antagonists are screened as potential 
pharmacotherapies for relapse prevention. Such approaches are used to elucidate the 
neurobiological and neurochemical mechanisms that mediate relapse. Our test drug of abuse, 
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oxycodone, has been used in only a limited capacity in preclinical studies on reinstatement of self-
administration, compared to other opioids such as heroin and morphine.  
In a 2005 study, investigators tested the hypothesis that co-administration of ultra-low-
doses of naltrexone, a mu-opioid antagonist, with oxycodone, a mu-opioid agonist, attenuate 
prime-, cue-, and stress-induced reinstatement [40]. Male Sprague-Dawley rats individually 
housed under a reverse light-dark cycle with ad libitum access to food and water, acquired 
oxycodone-reinforced self-administration behavior in combination with naltrexone (1, 10, 100 
pcg/kg/infusion) in 10 daily, three-hour sessions under an FR10 schedule of reinforcement. 
Subjects’ active lever-pressing behavior during acquisition and maintenance sessions resulted in 
an infusion of oxycodone infused over 10 seconds and a 30-second presentation of the light cue. 
Subjects’ active lever-pressing behavior during extinction sessions had no programmed 
consequences.  
In cue- and prime-reinstatement sessions (0.25 mg/kg, SC), subjects that previously self-
administered ultra-low doses of naltrexone (1, 10 pcg/kg/infusion) in combination with oxycodone 
showed attenuated levels of responding. In stress-induced reinstatement sessions, subjects that 
previously self-administered naltrexone in combination with oxycodone showed a naltrexone 
dose-dependent attenuation in responding. Such a result is a successful demonstration of the ability 
to alter reinstatement of lever-pressing behavior following extinction by manipulation of opioid 
neurotransmission. It is suggested, then, that patients initially acquiring a drug taking behavior 
with oxycodone and naltrexone in combination may be less liable to abuse opioids after treatment 
or abstinence from drug taking. 
In 2014 study, investigators tested the hypothesis that ATPM-ET, a kappa-opioid agonist 
with mixed mu-opioid agonist-antagonist activity, attenuates prime-induced reinstatement in 
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subjects receiving opioids [41]. Male Sprague-Dawley rats individually housed on a reverse light-
dark cycle acquired heroin-reinforced nose-poking behavior under a FR2 schedule of 
reinforcement (50 mcg/kg/infusion) in three-hour operant sessions, limited to 25 injections per 
session, for 10 consecutive days. In the acquisition phase, subjects were administered saline or 
ATPM-ET (1.2 or 2.4 mg/kg, IP) 15 minutes prior to session and subjects continued responding 
for 8 to 10 days until subjects could discriminate between the active and inactive hole for 3 
consecutive days. Subjects extinguished responding in daily three-hour extinction sessions for 3 
weeks where heroin solution was replaced with saline solution. In reinstatement tests, ATPM-ET 
(1.2 and 2.4 mg/kg, IP) or saline (1 ml/kg, IP) was injected 15 minutes prior to injection of heroin 
(0.25 mg/kg, SC) or saline (1 ml/kg, SC), which was injected 10 minutes prior to subject placement 
in chamber. It is reported that ATPM-ET at high doses attenuated the ability of heroin to reinstate 
active nose-poking behavior without affecting inactive nose-poking responding. It is suggested, 
then, that ATPM-ET may prevent heroin priming induced reinstatement of extinguished drug 
seeking behavior. 
In a 1996 study, investigators tested the hypothesis that dopamine antagonists attenuate 
prime- and stress-induced reinstatement in subjects receiving opioids [42]. Male Long-Evans rats 
housed on a reverse light-dark cycle, acquired heroin-reinforced lever-pressing behavior under a 
FR1 schedule of reinforcement (25 mcg/kg/infusion) in four, three-hour operant sessions per day, 
two sessions per light cycle, for eight to eleven consecutive days. In the extinction phase, subjects 
received an infusion of saline for pressing the previously reinforced lever for five consecutive 
days. Subsequently, subjects were tested twice, separated by 48 hours, for reinstatement of self-
administration of heroin under either prime or stress conditions in three-hour sessions where either 
non-contingent, subcutaneous heroin injection (0.25 mg/kg, 10-minute incubation) or intermittent 
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footshock (0.5 mA, 0.5 s active, 10-70 s inactive, 10-minute session) were given prior to session. 
As in the extinction phase, subjects received a saline infusion under reinstatement conditions for 
pressing the previously active lever. Subjects were pretreated with either saline, the opioid 
antagonist, naltrexone (1 or 10 mg/kg, SC), the D1-like receptor antagonist SCH 23390 (0.05 or 
0.1 mg/kg, IP), the D2-like receptor antagonist raclopride (0.25 or 0.5 mg/kg, IP), or the non-
selective DA antagonist flupenthixol (3 or 6 mg/kg, IM). In stress conditions, only flupenthixol 
dose-dependently attenuated reinstatement. In prime conditions, however, naltrexone, raclopride, 
and flupenthixol dose-dependently attenuated reinstatement.  
It is possible to conclude, then, that dopaminergic signaling plays an important role in 
reinstatement of behavior following exposure to aversive stimuli, or re-exposure to heroin, since 
flupenthixol, the non-selective dopaminergic antagonist attenuated both stress-induced and prime-
induced reinstatement in this procedure. However, these findings also suggest that stress-induced 
reinstatement and prime-induced reinstatement are also mediated by at least two different 
neurobiological or neurochemical systems since naltrexone and raclopride, which have different 
mechanisms of action than flupenthixol, attenuated prime-induced reinstatement, but not stress-
induced reinstatement. 
In a 2012 study, investigators tested the hypothesis that dopamine antagonists attenuate 
prime-induced reinstatement in subjects receiving opioids [43]. Food-restricted (20 g daily), male 
Sprague-Dawley rats housed on a reverse light-dark cycle acquired heroin-reinforced nose-poking 
behavior under a FR1 schedule of reinforcement (30 mcg/kg/infusion) in daily three-hour operant 
sessions for 12 to 14 days. In the extinction phase, subjects received an infusion of saline for nose-
poking the previously reinforced hole. Subsequently, subjects were tested for prime-induced 
reinstatement in two-hour sessions, where a non-contingent, subcutaneous heroin injection (0.25 
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mg/kg) was administered prior to session. In reinstatement sessions, prior to prime injection, 
subjects were treated with saline or levotetrahydropalmatine (1.25, 2.5, or 5 mg/kg, IP), a 
D1/D2/D3 antagonist. In prime conditions, levotetrahydropalmatine dose-dependently attenuated 
heroin prime-induced reinstatement—that is, that the number of nose-pokes in the active hole was 
significantly decreasing as a function of increasing treatment dose.  
It is common, in reinstatement studies, to include complementary data such as food-
reinforced lever press performance or locomotion data that indicate that a particular treatment 
produces a specific effect, or one that selectively modulates a single system or set of systems, and 
not a non-specific effect, that non-selectively modulates many or all systems. In this study, 
investigators elected to include nose-poke performance data on the non-reinforcing, or inactive 
nose-poke hole. These data suggest that the treatment mechanism is specific to a single system or 
a set of systems, such as the mesocorticolimbic dopamine system, which mediates behavior in 
accordance with a multiple-term contingency. Furthermore, data from locomotion assays indicate 
that only high doses of levotetrahydropalmatine (5 mg/kg, IP) significantly decrease locomotion, 
which reinforces the notion that the treatment acts directly and not through sedative effect. It is 
possible to conclude, then, that levotetrahydropalmatine may have therapeutic utility in the 
prevention of relapse prompted by re-exposure to drug. 
In a 2013 study, investigators tested the hypothesis that dopamine antagonists attenuate 
prime- and cue-induced reinstatement in subjects receiving opioids [44]. Male Sprague-Dawley 
rats individually housed on a reverse light-dark cycle acquired heroin-reinforced nose-poking 
behavior under a FR1 schedule of reinforcement (50 mcg/kg/infusion) in daily four-hour operant 
sessions for 14 days. In extinction sessions, there were no programmed consequences for behavior 
in daily one-hour sessions for 10 consecutive days. Subsequently, subjects were tested for 
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reinstatement of self-administration of heroin under cue conditions and prime conditions in two-
hour sessions. In cue conditions, visual and auditory cues were presented for five seconds at the 
start of the session and for each nose-poke on the previously reinforced hole thereafter. However, 
no reinforcement was delivered for behavior. In prime conditions, subjects were administered 
heroin (0.1 or 0.25 mg/kg, SC) 10 minutes prior to sessions in which no reinforcement was 
delivered for behavior. In cue conditions, risperidone (0.01, 0.03, or 0.1 mg/kg, IP), a D2/D3/D4 
antagonist, was administered 10 minutes prior to session, and in prime conditions, 10 minutes prior 
to prime injection.  
In cue conditions, risperidone (0.03 and 0.1 mg/kg, IP) pre-treatment dose-dependently 
attenuated reinstatement of nose-poking behavior on the active hole with no significant change in 
nose-poking behavior on the inactive hole. In heroin (0.1 or 0.25 mg/kg, SC) prime conditions, 
risperidone (0.01, 0.03, or 0.1 mg/kg, IP) pre-treatment had no significant effect on reinstatement 
of nose-poking behavior on either the active or inactive hole. Lai et al, suggest that while 
risperidone serves as an antagonist for numerous DA receptor subtypes, most notably D2 receptors, 
they also report that risperidone has a greater affinity for 5HT-2A receptors exerts similar action 
at adrenergic receptors and histamine receptors. It is possible to suggest, then, that risperidone, 
and drugs with similar mechanism of action, may have therapeutic utility in the prevention of 
relapse prompted by cues previously associated with drug-taking behavior. 
In a 2014 study, investigators tested the hypothesis that the mixed dopamine agonist-
antagonist, L-stepholidine, attenuates cue-induced reinstatement in subjects receiving an opioid 
agonist [45]. Male Sprague-Dawley rats housed on a reverse light-dark cycle acquired heroin-
reinforced nose-poking behavior under a FR1 schedule of reinforcement (30 mcg/kg/infusion) in 
daily two-hour operant sessions. In the acquisition phase, each infusion was paired with a 5 second 
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presentation of visual (light) and auditory (tone) cue. In the extinction phase, subjects’ responding 
had no programmed consequences for behavior. Subsequently, subjects were tested for cue-
induced reinstatement in two-hour operant sessions. In the reinstatement test sessions, subjects 
were pre-treated with saline or L-stepholidine (2.5, 5.0, 10.0 or mg/kg, IP) 30 minutes prior to 
session. In these sessions nose poking behavior was not reinforced with heroin. It is reported that 
L-stepholidine, but not saline, significantly and dose-dependently attenuates cue-induced 
reinstatement. Furthermore, L-stepholidine and saline had no significant effect on locomotor 
activity nor nose-poking behavior on the inactive hole.  
In a concurrent 2014 study, performed by the same group, investigators tested the 
hypothesis that the same mixed dopamine agonist-antagonist, L-stepoholidine, attenuates cue-
induced reinstatement in subjects receiving an opioid agonist [46]. Male Sprague-Dawley rats 
individually housed under a reverse light-dark cycle acquired heroin-reinforced nose-poking 
behavior under a FR1 schedule of reinforcement (50 mcg/kg/infusion) in daily three-hour operant 
sessions for 12 consecutive days. In the extinction phase, there were no programmed consequences 
for behavior in daily two-hour sessions for 12 consecutive days. Subsequently, subjects were tested 
for heroin prime-induced reinstatement (0.25 mg/kg, SC). In the reinstatement procedure, subjects 
pre-treated with saline or L-stepholidine (2.5, 5.0 or 10.0 mg/kg, SC) 30 minutes prior to session. 
It is reported that L-stepholidine, but not saline, significantly and dose-dependently attenuated 
heroin prime-induced reinstatement. Furthermore, L-stepholidine and saline had no significant 
effect on locomotor activity nor inactive nose-poking behavior on the inactive hole.  
Indeed, L-stepholidine is characterized as a dual D1-receptor agonist and D2-receptor 
antagonist [47–50]  and therefore supports the rationale for use of dopamine agonist-antagonist 
approaches to relapse control following opioid abuse. Since the dopamine receptor and its subtypes 
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have been major targets of investigation in the relapse to opioid abuse, the use of L-stepholidine 
is justified, even with mixed action at dopamine receptors.  However, others also report significant 
partial agonistic activity at 5-HT1A receptors [51]. It is possible to conclude then, that, while L-
stepholidine may decrease relapse liability, it may not mediate these effects through dopamine 
receptors alone. Overall, these pharmacological manipulations provide insight into the receptor 
mechanisms which mediate relapse to opioids, induced by both re-exposure to drug-associated 
cues and renewed drug taking. Collectively, these studies demonstrate that the mesocorticolimbic 
dopamine system is involved in the mediation of prime-, cue-, and stress-induced reinstatement of 
heroin-reinforced self-administration behavior.  
It should be noted that while the authors of each study characterize their experiments with 
a great degree of detail, no single study reported a complete set of controlled variables, which are 
necessary to make direct comparisons. For example, some studies explicitly state their acquisition 
and extinction criteria, while other studies differ in that they report only the number of operant 
sessions or the number of days required to meet an unspecified set of criteria. Furthermore, no two 
studies used exactly the same values in their set of controlled variables. Even experiments reported 
by the same group—seeking to answer nearly identical questions—in two separate publications in 
the same year, had marked variations in their procedures, including the drug infusion 
concentration. In addition, while most of the studied pre-treatment ligands are selective for a 
particular receptor or receptor subtype, these ligands tend to bind, to at least some degree, many 
different molecular targets. It should be noted, then, that the effects observed in the reviewed 
reinstatement assays may be due to a combination of ligand-receptor interactions, and not solely 
due to the interaction between the receptor and ligand with greatest affinity.  
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 In summary, many of these studies have demonstrated that receptors in the 
mesocorticolimbic dopamine system play a role in the modulation of effects of acute opioid 
exposure, opioid-associated cues, and stressors on the reinstatement of opioid seeking.  Overall, 
the reinstatement paradigm has been shown to be a viable platform for the investigation of relapse-
like behavior and the variables which may impact relapse including pharmacological, genetic and 
environmental variables. Our study utilized this well-established model to investigate the 
hypothesis that moderate TBI increases the risk for developing an opioid use disorder as measured 
by reinstatement of lever-pressing behavior previously reinforced by oxycodone in a self-
administration procedure, a proposed model of preoccupation and anticipation leading to relapse. 
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CHAPTER 2: PART 2 
2.6 CURRENT UNDERSTANDING OF PHYSICAL DEPENDENCE TO OPIOIDS 
In the development of drug addiction, drug taking often begins in a social setting and is 
compounded by acute reinforcement. Escalation of drug taking can lead to a transition from 
compulsive use to physical dependence and withdrawal symptoms following abstinence. It is 
proposed that dysphoria, a result of cessation of drug use in dependent individuals, may be a 
sufficient motivating factor in the reinitiation of drug taking, also known as relapse. According to 
Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, physical dependence refers 
to an “altered physiological state produced by the repeated administration of drug, which 
necessitates the continued administration of the drug to prevent the appearance of a stereotypical 
syndrome, the withdrawal or abstinence syndrome, characteristic for a particular drug” [52]. The 
development of physical dependence is not predicated on the motivating factors for drug taking 
such as misuse, abuse, and supervised medical use, rather it is the repeated drug administration 
alone that results in altered physiology [53,54].  
It is proposed that while these reinforcing effects serve to promote the initial development 
of drug taking through positive reinforcement, physical dependence is important in the 
continuation and maintenance of drug taking which serve to alleviate an aversive withdrawal 
syndrome, a form of negative reinforcement [55–59]. It follows then, that a withdrawal syndrome, 
as occurs with opioids, can be a major determinant of continued use and abuse of a drug [60]. In 
both preclinical and clinical studies, withdrawal will occur after abrupt cessation of chronic opioid 
intake, or spontaneous withdrawal [61], and through the administration of an opioid antagonist, or 
precipitated withdrawal [62]. Our study used this well-established approach to test the hypothesis 
that moderate TBI increases the risk for developing a physiological dependence to oxycodone as 
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measured by changes in food-reinforced lever-pressing and other withdrawal behaviors during 
both precipitated and spontaneous withdrawal. 
 It is reported that a strong correlation exists between the species specific withdrawal signs 
and symptoms of both humans and rodents with respect to physical dependence induced by 
repeated administration of opioids [63–66]. In humans, signs and symptoms of withdrawal include 
dysphoric mood, nausea or vomiting, muscle aches, cramps, lacrimation, rhinorrhea, pupillary 
dilation, piloerection, sweating, chills, diarrhea, yawning, fever, insomnia, craving for opioid drug, 
sneezing, tachycardia, and hypertension (see table for qualifying criteria) [67–70]. In rodents, signs 
and symptoms of withdrawal include diarrhea, rhinorrhea, piloerection, teeth chattering, “wet dog 
shakes,” genital grooming and penile erection and decreased food consumption (anorexia) [71].  
Operant responding has been shown as a sensitive measure in the detection of withdrawal 
signs and symptoms. For example, in a model of physical dependence, food-reinforced operant 
responding is disrupted in a precipitated withdrawal procedure by the administration of an opioid 
antagonist in opioid-dependent subjects [72,73]. Moreover, doses of an opioid antagonist that are 
sufficiently small to not result in observable withdrawal in morphine-dependent rats will disrupt 
food-reinforced responding [74]. Collectively, these studies suggest that the development of 
physical dependence as an adaptive, homeostatic response to the acute and chronic administration 
of opioids is well established in rodent models and can be quantified through gross observation of 
unlearned behavior and learned behavior as in schedule controlled responding [72,74,75].  
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Qualification Criteria for Withdrawal Syndrome 
[DSM 5]1 Opioid Withdrawal Diagnostic 
Criteria 292.0 (F11.23) 
[ICD-10]2 Opioid Withdrawal State 
Criteria (F11.3) 
A. Presence of either of the following: 
1. Cessation of (or reduction in) opioid use 
that has been heavy and prolonged (i.e., 
several weeks or longer).  
2. Administration of an opioid antagonist 
after a period of opioid use. 
B. Three (or more) of the following developing 
within minutes to several days after 
Criterion A:  
1. Dysphoric mood 
2. Nausea or vomiting 
3. Muscle Aches 
4. Lacrimation or rhinorrhea 
5. Pupillary dilation, piloerection, or 
sweating 
6. Diarrhea 
7. Yawning 
8. Fever 
9. Insomnia 
C. The signs or symptoms in Criterion B cause 
clinically significant distress or impairment 
in social, occupational, or other important 
areas of functioning 
D. The signs or symptoms are not attributable 
to another medical condition and are not 
better explained by another mental disorder, 
including intoxication or withdrawal from 
another substance 
A. The general criteria for withdrawal state 
(F1x.3) must be met. (Note that an 
opioid withdrawal state may also be 
induced by administration of an opioid 
antagonist after a brief period of opioid 
use.) 
B. F1x.3 Withdrawal State Criteria: 
1. There must be clear evidence of 
recent cessation or reduction of 
substance use 
after repeated, and usually prolonged 
and/or high-dose, use of that substance. 
2. Symptoms and signs are compatible 
with the known features of a withdrawal 
state from the particular substance or 
substances (see below). 
3. Symptoms and signs are not 
accounted for by a medical disorder 
unrelated to 
substance use, and not better accounted 
for by another mental or behavioral 
disorder. 
C. Any three of the following signs must 
be present: 
1. Craving for an opioid drug  
2. Rhinorrhoea or sneezing 
3. Lacrimation 
4. Muscle aches or cramps 
5. Abdominal cramps 
6. Nausea or vomiting; 
7. Diarrhea 
8. Pupillary dilatation 
9. Piloerection, or recurrent chills 
10. Tachycardia or hypertension 
11. Yawning 
12. Restless sleep 
 
[1] American Psychiatric Association., (2013). Diagnostic and Statistical Manual of Mental 
Disorders, 5th Edition (DSM-5). 
[2] World Health Organization., (2010). International Classification of Diseases (ICD). 
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CHAPTER 3: MATERIALS AND METHODS 
3.1 SUBJECTS 
Subjects were adult male Sprague-Dawley rats individually housed under a reverse light-
dark cycle (light 1800 to 0600; dark 0600 to 1800) with ad libitum access to food and water in a 
vivarium approved by the Association for Assessment and Accreditation of Laboratory Animal 
Care (AAALAC). All procedures were reviewed and approved by the Virginia Commonwealth 
University (VCU) Institutional Animal Care and Use Committee (IACUC) and the Animal Care 
and Use Review Office (ACURO) of the United States Army Medical Research and Materiel 
Command (USAMRMC) Office of Research Protections (ORP). 
3.2 FLUID PERCUSSION INJURY PROCEDURE 
Subjects underwent a fluid percussion procedure to induce moderate, closed-head, 
intracranial injury (Day 0) following handling, operant training, and when appropriate intravenous 
catheterization for subsequent behavioral procedures.  Subjects were anesthetized with 3 percent 
isoflurane vapor and transferred to a stereotaxic device for craniectomy and maintained on 4 
percent isoflurane for the duration of the procedure. Subjects were divided approximately evenly 
into two groups: 1) a control group that underwent all procedures with the exception of the fluid 
percussion injury (referred to as control, non-injured, or sham subjects) and 2) a treatment group 
that underwent all procedures including the fluid percussion injury (referred to as injured, brain-
injured, or TBI subjects). 
One longitudinal incision of 9 mm in length was made in the scalp and the underlying 
fascia was displaced to expose the dorsal surface of the exterior skull. A craneictomy of 4.8 mm 
in diameter was then performed by hand with a trephine over the right motor cortex at the midpoint 
between bregma and lambda and the central fissure and lateral ridge. A cannula fabricated from 
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the hub of a female leur-lock compatible 20-gauge needle was affixed to the skull at the 
craniectomy site and secured to the skull with dental acrylic. Once the dental acrylic hardened, the 
cannula was filled with sterile saline and the intracranial injury was induced with a fluid percussion 
device (Custom Design and Fabrication, VCU, Richmond, VA). Subsequently, a visual 
observation to confirm the integrity of the dura mater was performed. A piezoelectric sensor in the 
fluid percussion device measured the profile of the pressure pulse and an oscilloscope recorded 
and reported the resultant amplitude and duration of the pressure pulse.  
Subjects’ transient loss of consciousness was assessed immediately after the procedure by 
measurement of the righting reflex assessed by the time each subject required to reorient itself to 
the prone position when placed in the on its back. It reported by numerous sources that the time to 
return of the righting reflex, is a valid measure of the extent and severity of tissue damage [76–
82]. After these procedures, the scalp was closed with a polydioxanone suture and the subject was 
returned to a clean, warmed, home chamber for recovery.  
Statistical analysis of the recorded time to return of righting reflex between the brain-
injured and non-injured subjects was performed using both a Student’s T-Test and a Levene’s Test 
for Equality of Variances. Subjects whose recorded time to return to right reflex was greater than 
two standard deviations from the mean did not qualify for inclusion in experiments and were 
excluded from calculations in the final data analysis. 
3.3 CATHETERIZATION PROCEDURE 
Subjects for testing in the self-administration procedure underwent surgical implantation 
of an indwelling, polyurethane catheter five days prior (Day -5) to the fluid percussion procedure 
(Day 0). Subjects were pre-medicated with 2 mg/kg morphine and anesthetized with 4 percent 
isoflurane vapor and maintained for the duration of the procedure. One longitudinal incision of 
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approximately 20 mm in length was made in the skin on the ventral surface of the neck, right 
lateral and parallel to the trachea in line with the point of the mandible. A blunt dissection 
technique was performed to locate and isolate a 10 mm segment of the right external jugular vein. 
Once the vein was located and isolated, the cranial end of the segment was ligated with a braided 
nylon suture. Subsequently, a latitudinal incision was made on the ventral surface of the vein. A 
polyurethane catheter was inserted into the vein and adjusted such that the final position of the 
catheter was at a level near, but not obstructing the right atrium. Once the catheter positioning was 
complete and catheter patency verified, braided nylon sutures were placed proximal and distal to 
the catheter cuff to secure the catheter to the vessel and these ties were used to anchor the catheter 
to the surrounding fascia.  
Subsequently, the subject was placed ventral side down on the surgical surface and one 
longitudinal incision of 20 mm in length was made 10 mm right lateral to the mid-scapular point. 
A second longitudinal incision of 3 mm in length was made at the mid-scapular point and the 
cannula pedestal was inserted subcutaneously through the dorsal incision of 20 mm in length and 
the upper post exposed through the dorsal incision of 3 mm in length.  After, the distal end of the 
catheter was passed subcutaneously from the ventral incision to the dorsal incision and secured to 
the cannula pedestal and catheter patency verified again with sterile saline. Subsequently, all 
incisions were closed with Michel wound clips. Catheter maintenance included a daily flush with 
a sterile solution of 20 mg/kg amoxicillin, 10 mg/kg sublactam, 250 units/ml of heparin sodium in 
a solution of 75 percent saline, 25 percent glycerol by volume.  Catheter patency was verified at 
periodic intervals with an intravenous administration of 7.5 mg/kg ketamine solution and 
confirmed by the presence immediate onset sedation.  
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3.4 SELF-ADMINISTRATION PROCEDURE 
On Day 5, subjects began self-administration testing conducted in standard operant 
chambers housed within isolated and ventilated enclosures (Med Associates, Saint Albans, VT). 
Each chamber was equipped with two response levers, a white stimulus light above each lever, 
and a five-watt chamber light. Before each session, infusion tubing, protected by a stainless steel 
spring tether (Plastics One, Roanoke, VA), was connected to the upper post of the implanted 
cannula pedestal and the tether secured. Subsequently, infusions were delivered via a peristaltic 
pump located outside of each enclosure. Control of the schedule parameters was performed with 
MED-PC IV software and hardware (Med Associates, Saint Albans, VT). Subjects were 
transported from the vivarium to the laboratory each day and allowed to acclimate for 15 to 30 
minutes prior to testing. In acquisition and maintenance sessions, each lever press on the 
designated active lever (right lever), resulted in a 3-second infusion of 0.1-ml of 0.03 mg/kg 
oxycodone solution and activation of the white stimulus light above the right lever. In this regard, 
the white stimulus light paired with the delivery of oxycodone served as a conditioned cue. 
Furthermore, the chamber light served as a discriminative stimulus signaling the availability of the 
reinforcer. A 60-second timeout was imposed following each infusion during which the chamber 
light was inactivated, and depression of the active lever was recorded but did not result in infusion 
delivery.  In these sessions, all lever-pressing behavior on the inactive lever (left lever) was 
recorded, but had no programmed consequences. Subjects’ self-administration behavior met 
acquisition criteria when the number of responses emitted was greater than or equal to 15 on the 
active lever, and the number of responses on the active lever was greater than on the inactive lever 
for three consecutive sessions. Once a subject met acquisition criteria, they continued testing in 
self-administration sessions until they met stable maintenance criteria. Stable performance was 
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defined as a period of three consecutive days during which the daily mean number of infusions did 
not differ from the mean number of infusions by more than 25 percent and no trends of increasing 
or decreasing behavioral performance were evident.  
Once subjects’ behavior met stable maintenance criteria, subjects were tested in extinction 
sessions during which responses on the active lever had no programmed consequences. In other 
words, responding did not result in the delivery of oxycodone or presentation of oxycodone-
associated cues, such as the white stimulus light. Subjects continued testing in extinction sessions 
until self-administration behavior met extinction criteria.  Extinction criteria was defined as three 
consecutive days with response levels less than 50 percent of the level of responses during stable 
maintenance performance. 
Once subjects’ behavior met extinction criteria, subjects were tested in reinstatement 
sessions for oxycodone prime-induced reinstatement (0.3, 1 mg/kg) or oxycodone-associated cue-
induced reinstatement. In prime-induced reinstatement sessions, conditions were identical to those 
conditions in the extinction sessions, however, 15 minutes prior to the session, a single non-
contingent injection of 0.3 or 1 mg/kg, subcutaneous (SC) oxycodone was delivered by the 
experimenter.  In cue-induced reinstatement sessions, conditions were similar to those conditions 
in extinction sessions, however, depression of the designated active lever resulted in the 
illumination of the white stimulus light above the designated active lever. Subjects’ testing for 
reinstatement of lever-pressing behavior was counterbalanced for order, and subjects resumed 
daily extinction sessions for at least three consecutive days and until performance met extinction 
criteria between reinstatement tests.  
Statistical analysis was performed on data collected including responses on the designated 
active lever, responses on the designated inactive lever, and responses during the timeout period. 
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Significant main effects were determined with a Two-Way ANOVA with between subject factors 
of fluid percussion condition (injured or non-injured) and schedule parameter (maintenance, 
extinction, cue-induced reinstatement, or prime-induced reinstatement).  
3.5 PHYSICAL DEPENDENCE PROCEDURE 
3.5.1 PRECIPITATED WITHDRAWAL ASSAY 
Two weeks prior to fluid percussion procedure on Day 0, subjects began training to emit 
lever-pressing behavior for food pellet reinforcement under a FR5 schedule in daily 100-minute 
sessions. Each session was comprised of five identical 20-minute trials. Each trial consisted of 
three components presented in the following order: a 15-minute time-out period in which the 
house-light was not illuminated and both left and right lever were absent; a 2-minute response 
period in which the house-light was illuminated, the right lever was present and completion of a 
FR5 on the right lever resulted in the presentation of a food pellet reinforcer; a 3-minute 
observation period in which the house-light remained on, but both levers were absent. Once food-
reinforced lever-pressing behavior was reliably established, subjects underwent the fluid 
percussion injury procedure as described above, designated Day 0. On Day 6, dose effect curves 
using cumulative doses of naltrexone (0, 1, 3, 10, 20 mg/kg, SC) were determined for suppression 
of food-reinforced lever-pressing behavior and production of other withdrawal signs.  Each dose 
was administered at the beginning of every 15-minute time-out period. In the 3-minute observation 
period, precipitated withdrawal signs were scored as present or absent in three 1-minute intervals. 
Opioid withdrawal signs measured included jumping, teeth chattering, salivation, face rubbing, 
abdominal stretches, erection/genital grooming, wet dog shakes, ptosis, diarrhea, and lethargy.  
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On Day 6 at approximately 1800, following the determination of the baseline naltrexone 
dose response curve, subjects were surgically implantated with sterile osmotic pumps (2ML2, 
Alzet, Cupertino, CA). Subjects were anesthetized with 3 percent isoflurane vapor and one 
longitudinal incision of approximately 20 mm in length was made on the back of each subject. 
Blunt dissection of the fascia was performed to create sufficient space for accommodation of an 
osmotic pump, which was then implanted subcutaneously and the surgical site closed with Michel 
would clips. Subjects were divided approximately evenly into two groups: 1) a control group that 
received osmotic pumps charged with a solution of sterile saline, and 2) a treatment group that 
received osmotic pumps charged with a solution of oxycodone.  A solution of oxycodone was 
made to a concentration that allowed for the continuous and non-contingent delivery of 12 
mg/kg/day (6x the ED80 value determined in an acute model of antinociception using a tail 
immersion assay) at a rate of 5 microliters per hour for a total of 14 days. On Day 11, dose effect 
curves using cumulative doses of naltrexone (0, 0.03, 0.1, 0.3, 1, 3, 10, 20 mg/kg, SC) were re-
determined to assess changes in food-reinforced responding and withdrawal scores following 
continuous treatment with saline or oxycodone. 
Statistical analysis was performed on data collected including responses on the active lever 
for food pellet reinforcer and mean composite withdrawal scores as assessed by the experimenter. 
Significant main effects were determined with a Two-Way ANOVA with between subject factors 
of fluid percussion condition (injured or non-injured) and osmotic pump treatment condition 
(continuous oxycodone or continuous saline).  
3.5.2 SPONTANEOUS WITHDRAWAL ASSAY 
On Day 12, subjects began training to emit lever-pressing behavior for food pellet 
reinforcement under an FR5 schedule in three daily 30-minute, single-trial operant sessions. Each 
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session consisted of three components presented in the following order: a 15-minute time-out 
period in which the house-light was not illuminated and both levers were absent; a 5-minute 
response period in which the house-light was illuminated, the right lever was present, and 
completion of a FR5 on the right lever resulted in the presentation of a food pellet reinforcer; and 
a 10-minute observation period in which the house-light was on, but both levers were absent. On 
Day 15 or 16, once food-reinforced behavior was reliably established, changes in food-reinforced 
behavior and other withdrawal signs were assessed as previously described at approximately 0600, 
1200, and 1800.  
On Day 16 at approximately 2400, subjects were anesthetized with 4 percent isoflurane 
vapor and one latitudinal incision of approximately 20 mm in length was made on the back of each 
subject. Subsequently, the implanted osmotic pumps were removed and the surgical site closed 
with Michel surgical clips. On Day 17, changes in food-reinforced responding and other 
withdrawal signs were again assessed as previously described three times per day at approximately 
0600, 1200, and 1800 for 60 hours. 
Statistical analysis was performed on data collected including responses on the designated 
active lever for food pellet reinforcer, and mean composite withdrawal scores as assessed by the 
experimenter. Significant main effects were determined with a Three-Way ANOVA with between 
subject factors of fluid percussion condition (injured or non-injured) and osmotic pump treatment 
condition (continuous oxycodone or continuous saline), and time (18, 12, 6 hours prior to pump 
removal; 6, 12, 18, 30, 36, 42, 54, and 60 hours post pump removal).  
3.5.2.1 LOCOMOTOR ACTIVITY ASSESSMENT 
 On Day 15 or 16, subjects were placed in an open field chamber (41cm X 41 cm X 20 cm) 
equipped with 16 photobeam cells (ENV15, Med Associates, Saint Albans, VT) and allowed to 
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ambulate freely for 30 minute, twice per day at approximately 0900 and 1500. On Day 17, subjects 
were assessed for changes in locomotion during 30-minute sessions at approximately 0900 and 
1500 and testing was repeated throughout the 60-hour spontaneous withdrawal assessment. 
Distance traveled was determined based on photobeam breaks and was recorded and analyzed 
using MedPC software (Med Associates, Saint Albans, VT).  
Statistical analysis was performed on data collected including the total distance traveled by 
each subject. Significant main effects were determined with a Three-Way ANOVA with between 
subject factors of fluid percussion condition (injured or non-injured) and osmotic pump treatment 
condition (continuous oxycodone or continuous saline), and time (18, 12, 6 hours prior to pump 
removal; 6, 12, 18, 30, 36, 42, 54, and 60 hours post pump removal).   
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CHAPTER 4: RESULTS 
4.1 SELF-ADMINISTRATION PROCEDURE 
For those subjects tested in the self-administration procedure, brain-injured subjects (n = 
14; 606.73 ± 26.31), relative to non-injured subjects (n = 9; 288.22 ± 18.61), required significantly 
more time to restore the righting reflex; t(22) = 8.586, p < 0.001. (FIGURE 1). In oxycodone-
reinforced sessions, brain-injured subjects (10.93 ± 0.78) showed no significant difference in the 
mean number of sessions required to meet criteria for stable maintenance for lever-pressing 
behavior relative to non-injured subjects (16.44 ± 3.14); t(9.010) = -1.705, p = 0.122 (FIGURE 
2). In non-reinforced extinction sessions, brain-injured subjects (10.67 ± 1.38) showed no 
significant difference in the mean number of sessions required to meet criteria for extinction of 
lever-pressing behavior relative to non-injured subjects (6.56 ± 1.14); t(22) = 2.059, p = 0.052 
(FIGURE 3). During stable maintenance of oxycodone-reinforced lever-pressing behavior, brain-
injured subjects (22.29 ± 1.50) emitted fewer oxycodone-reinforced lever presses than did non-
injured subjects (28.19 ± 8.66) [F (1, 155) = 20.102, P < 0.001] (FIGURE 4). During extinction 
of lever-pressing behavior, there were no significant differences in active lever responding 
between brain-injured subjects and non-injured subjects (FIGURE 4).  
Once extinction criteria for lever-pressing behavior were met, all subjects were tested for 
oxycodone-associated cue- and oxycodone prime-induced reinstatement (1 mg/kg, SC). A subset 
of all subjects (n = 4, brain-injured; n = 6, non-injured), were also tested for oxycodone prime-
induced reinstatement with 0.3 mg/kg, SC oxycodone administered prior to session start. In 
reinstatement test sessions, brain-injured subjects lever-pressing behavior under oxycodone-
associated cue- and oxycodone prime-induced conditions showed no significant differences 
relative to lever-pressing behavior during extinction sessions (FIGURE 4). However, non-injured 
  
36 
subjects’ lever-pressing behavior (18.22 ± 3.96) showed significant increases relative to lever-
pressing behavior in extinction sessions (10.30 ± 3.64) under oxycodone-associated cue-induced 
reinstatement conditions, but not oxycodone prime-induced reinstatement conditions [F (1, 155) = 
16.627, p < 0.001] (FIGURE 4). In these same tests, while brain-injured subjects showed no 
significant differences in inactive lever responding from non-injured subjects during acquisition 
sessions, brain-injured subjects emitted significantly fewer inactive lever presses during extinction 
sessions (7.57 ± 1.55) than did the non-injured subjects (11.04 ± 2.65) [F (1, 155) = 5.261, p < 
0.05] (FIGURE 5). However, both brain-injured subjects (1.93 ± 0.67) and non-injured subjects 
(6.00 ± 2.74) showed decreases in inactive lever-pressing behavior during tests for oxycodone 
prime-induced reinstatement (1 mg/kg, SC) relative to lever-pressing behavior during extinction 
sessions [F (1, 155) = 3.744, p < 0.05] (FIGURE 5). During timeouts, there were no significant 
differences in lever-pressing behavior between brain-injured subjects and non-injured subjects in 
acquisition sessions, extinction sessions, or oxycodone prime-induced reinstatement sessions 
(FIGURE 6). However, in test sessions for oxycodone-associated cue-induced reinstatement, non-
injured subjects showed an increase in lever-pressing behavior (52.67 ± 38.89) emitted during 
timeouts which was significantly greater than their timeout responding in acquisition sessions 
(37.93 ± 13.10) and extinction sessions (13.89 ± 4.85) [F (2, 155) = 9.308, p < 0.001] (FIGURE 
6). 
In the subset of subjects tested for oxycodone prime-induced reinstatement (0.3 mg/kg, 
SC), during oxycodone maintenance, brain-injured subjects’ lever-pressing behavior on the active 
lever (20.83 ± 1.52) was significantly less than lever-pressing behavior of non-injured subjects on 
the active lever (29.22 ± 3.36) [F (1, 64) = 3.744, p < 0.05] (FIGURE 7). However, during 
extinction sessions, there were no significant differences in active lever responding between brain-
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injured and non-injured subjects (FIGURE 7). In the reinstatement test sessions, brain-injured 
subjects showed lever-pressing behavior on the active lever (9.25 ± 1.31) that was similar to lever-
pressing behavior during extinction sessions (7.75 ± 0.61), while non-injured subjects showed a 
significant increase in lever-pressing behavior on the active lever (19.83 ± 6.32) relative to lever-
pressing behavior during extinction sessions (10.94 ± 1.21) [F (2, 64) = 36.48, p < 0.001] 
(FIGURE 7). In these same tests, there was no significant difference in inactive lever-pressing 
behavior regardless of the schedule parameters or injury condition (FIGURE 8). During timeouts, 
brain-injured subjects showed decreases in lever-pressing behavior relative to lever-pressing 
behavior by non-injured subjects regardless of the schedule parameters, however this difference 
between brain-injured subjects (15 ± 3.97) and non-injured subjects (34.94 ± 17.27) was only 
significant during acquisition when oxycodone served to reinforce lever-pressing behavior [F (1, 
64) = 4.860, p < 0.05] (FIGURE 9).  
4.2 PHYSICAL DEPENDENCE PROCEDURE 
4.2.1 PRECIPITATED WITHDRAWAL ASSAY 
For those subjects tested in the physical dependence procedure, brain-injured subjects (n = 
22; 693.00 ± 39.38), relative to non-injured subjects (n = 15; 279.13 ± 11.32) required significantly 
more time to restore the righting reflex; t(24.367) = 10.100, p < 0.001 (FIGURE 10). On Day 6, 
prior to pump implantation, the mean withdrawal scores observed in response to challenge with 
naltrexone approached a value of zero for both brain-injured subjects and non-injured subjects 
with no significant differences observed across injury condition (FIGURE 11, 12, 13, 14). 
Similarly, there were no significant differences in mean withdrawal scores observed in response 
to challenge with naltrexone between brain-injured and non-injured subjects after treatment with 
continuously delivered oxycodone (FIGURE 11). However, the mean withdrawal scores observed 
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for subjects of both injury conditions were significantly elevated when challenged with naltrexone 
after treatment with continuously delivered oxycodone relative to when challenged with vehicle 
[F (4,65) = 23.300, p < 0.001] (FIGURES 11, 13, 14). In brain injured and non-injured subjects 
treated with continuously delivered saline, there were no significant and biologically relevant 
differences in mean withdrawal scores when challenged with naltrexone (FIGURE 12, 13, 14). 
Overall, there were no significant differences in naltrexone-generated mean withdrawal scores 
between brain-injured subjects and non-injured subjects before or after treatment with 
continuously delivered oxycodone (FIGURE 11) or saline (FIGURE 12). 
In subjects treated with continuously delivered oxycodone, there was a significant 
difference in the mean number of food-reinforced lever presses before treatment for brain-injured 
subjects and non-injured subjects when challenged with a dose of 3 mg/kg, SC naltrexone [F (1, 
75) = 5.449, p < 0.05] and after treatment when challenged with the dose of 0.03 mg/kg, SC 
naltrexone [F (1, 60) = 3.976, p < 0.05] (FIGURES 15, 17, 18). However, there was no significant 
difference in the mean number food-reinforce lever presses between brain-injured and non-injured 
subjects when challenged with vehicle either before or after treatment with continuously delivered 
oxycodone (FIGURE 15). Conversely, in subjects treated with continuously delivered saline, 
brain-injured subjects and non-injured subjects showed significant baseline differences in the mean 
number of lever presses both before [F (1, 80) = 24.530, p < 0.001] and after treatment with 
continuously delivered oxycodone [F (1, 80) = 7.967, p < 0.05] with the non-injured subjects 
showing greater lever-pressing behavior (FIGURE 16). Moreover, non-injured subjects 
demonstrated greater lever-pressing behavior when challenged with naltrexone across all but the 
highest dose tested after treatment with continuous saline (FIGURE 16). In both brain-injured 
subjects [F (7, 87) = 8.379, p < 0.001] (FIGURE 17) and non-injured subjects [F (7, 53) = 13.726, 
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p < 0.001] (FIGURE 18) treated with continuously delivered oxycodone, a challenge with 
naltrexone after treatment produced a dose-dependent (0.03, 0.1, 0.3 mg/kg, SC) attenuation in the 
mean number of food-reinforced lever presses relative to the mean number of food-reinforced lever 
presses after treatment with continuously delivered saline.  
4.2.2 SPONTANEOUS WITHDRAWAL ASSAY 
In the spontaneous withdrawal assay, there were no significant differences in mean 
withdrawal scores across time between brain-injured subjects and non-injured subjects after 
treatment with continuously delivered oxycodone (FIGURE 19) or saline (FIGURE 20). In brain-
injured subjects treated with continuous delivered oxycodone, mean withdrawal scores were 
elevated at the 6 [F (1, 207) = 31.772, p < 0.001], 12 [F (1, 207) = 75.316, p < 0.001], 18 [F (1, 
207) = 32.161, p <0.001], and 36 [F (1, 207) = 4.255, p <0.05] hour time points relative to brain-
injured subjects treated with continuously delivered saline (FIGURE 21). In non-injured subjects 
treated with continuously delivered oxycodone, mean withdrawal scores were significantly 
elevated at the 6 [F (1, 143) = 23.209, p < 0.001], 12 [F (1, 143) = 21.809, p < 0.001], 18 [F (1, 
143) = 41.629, p < 0.001], 30 [F (1, 143) = 6.472), p < 0.05], 36 [F (1, 143) = 4.520, p < 0.05], 
and 42 [F (1, 143) = 9.591, p < 0.05] hour time points relative to non-injured subjects treated with 
continuously delivered saline (FIGURE 22).  
In subjects treated with continuously delivered oxycodone, there were no significant 
differences in the mean number of food pellets earned between brain-injured or non-injured 
subjects at any of the time points before or after pump removal (FIGURE 23). Similarly, in 
subjects treated with continuously delivered saline, there were no significant and biologically 
relevant differences in the mean number of food pellets earned between brain-injured and non-
injured subjects at any of the time points before or after pump removal (FIGURE 24). In brain-
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injured subjects, those treated with continuously delivered oxycodone showed significant 
decreases in the mean number of food pellets earned at the 6 [F (1, 209) = 4.283, p < 0.05)], 12 [F 
(1, 209) = 8.558, p < 0.01), and 18 [F (1, 209) = 3.852, p < 0.05] hour time points relative to those 
subjects treated with continuous saline (FIGURE 25). In non-injured subjects, those treated with 
continuously delivered oxycodone showed significant decreases in the mean number of food 
pellets earned at all time points [F (10, 142) = 2.363, p < 0.05] (FIGURE 26).  
4.2.2.1 LOCOMOTOR ACTIVITY ASSESSMENT 
 In the assessment of locomotor activity, brain-injured subjects that were treated with 
continuously delivered oxycodone showed significant decreases in distance traveled at the 9 [F (1, 
198) = 17.431, p < 0.001], 33 [F (1, 198) = 7.543, p < 0.01], and 57 [F (1, 198) = 4.905, p < 0.05] 
hour time points, relative to brain-injured subjects that were treated with continuously delivered 
saline (FIGURE 27).  Subjects that were non-injured and treated with continuously delivered 
oxycodone showed significant decreases in distance traveled at the 9 [F (1, 198) = 8.679, p < 0.01], 
15 [F (1, 198) = 4.418, p < 0.05], and 33 [F (1, 198) = 10.466, p < 0.001] hour time points, relative 
to non-injured subjects that were treated with continuously delivered saline (FIGURE 27). 
Overall, while subjects treated with continuously delivered saline traveled significantly greater 
total distances relative to subjects treated with continuously delivered oxycodone, there were no 
significant differences in total distance traveled within treatment groups based on injury condition.   
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FIGURE 1. Shown are the mean times required for the return of the righting reflex in seconds (± 
standard error) for subjects tested in the self-administration procedure (n = 9, control; n = 14, 
injured). * significantly different from control, p < 0.05. 
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FIGURE 2. Shown are the mean number of sessions with oxycodone available (± standard 
error) required by subjects to meet stable maintenance criteria (n = 9, control; n = 14, injured). * 
significantly different from control at p < 0.05. 
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FIGURE 3. Shown are the mean number of sessions (± standard error) without oxycodone 
available required by subjects to meet extinction criteria (n = 9, control; n = 14, injured). * 
significantly different from control at p < 0.05. 
  
  
44 
A C Q E X T C U E 1 P R
0
5
1 0
1 5
2 0
2 5
3 0
3 5
R e in s ta te m e n t  -  A c t iv e  L e v e r
L
e
v
e
r
 P
r
e
s
s
e
s
 ±
S
E
M
C O N TR O L
IN J U R E D
*
&
*
&
 
FIGURE 4. Shown are the mean number of responses on the active lever (± standard error) 
during FR1 oxycodone reinforced sessions (ACQ), following extinction training (EXT), during 
cue- induced (CUE) and 1 mg/kg SC oxycodone prime-induced reinstatement (1PR) (n = 9, 
control; n = 14, injured). * significantly different from control, p < 0.05. & significantly different 
from extinction baseline within injury condition, p < 0.05. 
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FIGURE 5. Shown are the mean number of responses on the inactive lever (± standard error) 
during FR1 oxycodone reinforced sessions (ACQ), following extinction training (EXT), during 
cue- induced (CUE) and 1 mg/kg SC oxycodone prime-induced reinstatement (1PR) (n = 9, 
control; n = 14, injured). * significantly different from control injury, p < 0.05. & significantly 
different from extinction baseline within injury condition, p < 0.05.
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FIGURE 6. Shown are the mean number of responses in the time out  (± standard error) during 
FR1 oxycodone reinforced sessions (ACQ), following extinction training (EXT), during cue- 
induced (CUE) and 1 mg/kg SC oxycodone prime-induced reinstatement (1PR) (n = 9, control; n 
= 14, injured). * significantly different from control injury, p < 0.05. & significantly different 
from extinction baseline within injury condition, p < 0.05. 
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FIGURE 7. Shown are the mean number of responses on the active lever (± standard error) 
during FR1 oxycodone reinforced sessions (ACQ), following extinction training (EXT), and 0.3 
mg/kg SC oxycodone prime-induced reinstatement (.3PR) (n = 6, control; n = 4, injured). * 
significantly different from control injury, p < 0.05. & significantly different from extinction 
baseline within injury condition, p < 0.05. 
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FIGURE 8. Shown are the mean number of responses on the inactive lever (± standard error) 
during FR1 oxycodone reinforced sessions (ACQ), following extinction training (EXT), and 0.3 
mg/kg SC oxycodone prime-induced reinstatement (.3PR) for sham controls (n = 6) and brain-
injured (n = 4) subjects. * significantly different from control injury, p < 0.05. & significantly 
different from extinction baseline within injury condition, p < 0.05. 
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FIGURE 9. Shown are the mean number of responses in the time out (± standard error) during 
FR1 oxycodone reinforced sessions (ACQ), following extinction training (EXT), and 0.3 mg/kg 
SC oxycodone prime-induced reinstatement (.3PR) for sham controls (n = 6) and brain-injured (n 
= 4) subjects. * significantly different from control injury, p < 0.05. & significantly different 
from extinction baseline within injury condition, p < 0.05. 
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FIGURE 10. Shown are the mean times required for the return of the righting reflex righting in 
seconds (± standard error) for subjects tested in the physical dependence procedure (n = 15, 
control; n = 22, injured). * significantly different from control, p < 0.05. 
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FIGURE 11. Shown are the mean withdrawal scores (± standard error) during baseline (PRE 
dosing curves) and precipitated withdrawal sessions (POST dosing curves) induced by 0.03, 0.1, 
0.3, 1, 3, 10, and 20 mg/kg SC naltrexone for sham control (n = 7) and brain-injured subjects (n 
= 11) continuously delivered oxycodone 12 mg/kg/day for 5 days. 
 
  
  
52 
0
2
4
6
8
1 0
P re c ip ita te d  W ith d ra w a l -  S A L
N a ltre x o n e  (m g /k g , s c )
W
it
h
d
r
a
w
a
l 
S
c
o
r
e
 ±
S
E
M
V E H 1 20
S H A M  P O S T
S H A M  P R E
IN J U R E D  P O S T
IN J U R E D  P R E
3 10
*
 
FIGURE 12. Shown are the mean withdrawal scores (± standard error) during baseline (PRE 
dosing curves) and precipitated withdrawal sessions (POST dosing curves) induced by 1, 3, 10, 
and 20 mg/kg SC naltrexone for sham control (n = 7) and brain-injured subjects (n = 11) 
continuously delivered saline for 5 days. * significantly different from injury control, p < 0.05. 
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FIGURE 13. Shown are the mean withdrawal scores (± standard error) during baseline (PRE 
dosing curves) and precipitated withdrawal sessions (POST dosing curves) induced by 0.03, 0.1, 
0.3, 1, 3, 10, and 20 mg/kg SC naltrexone for brain-injured subjects continuously delivered 
saline (n = 11) or oxycodone 12 mg/kg/day (n = 11) for 5 days. * significantly different from 
vehicle p < 0.05. 
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FIGURE 14. Shown are the mean withdrawal scores (± standard error) during baseline (PRE 
dosing curves) and precipitated withdrawal sessions (POST dosing curves)  induced by 0.03, 0.1, 
0.3, 1, 3, 10, and 20 mg/kg SC naltrexone for sham control subjects continuously delivered saline 
(n = 7) or oxycodone 12 mg/kg/day (n = 7) for 5 days. *significantly different from vehicle p < 
0.05. 
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FIGURE 15. Shown are the mean number of food-reinforced lever presses emitted (± standard 
error) during baseline (PRE dosing curves) and precipitated withdrawal sessions (POST dosing 
curves) induced by 0.03, 0.1, 0.3, 1, 3, 10, and 20 mg/kg SC naltrexone for sham control (n = 7) 
and brain-injured (n = 11) subjects continuously delivered oxycodone 12 mg/kg/day for 5 days. * 
significantly different from injury control post-treatment. p < 0.05; & significantly different from 
injury control pre-treatment, p < 0.05. 
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FIGURE 16. Shown are the mean number of food-reinforced lever presses emitted (± standard 
error) during baseline (PRE dosing curves) and precipitated withdrawal sessions (POST dosing 
curves) induced by 1, 3, 10, and 20 mg/kg SC naltrexone for sham control (n = 7) and brain-
injured (n = 11) subjects continuously delivered saline for 5 days. * significantly different from 
injury control post-treatment. p < 0.05; & significantly different from injury control pre-
treatment, p < 0.05. 
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FIGURE 17. Shown are the mean number of food-reinforced lever presses emitted (± standard 
error) during baseline (PRE dosing curves) and precipitated withdrawal sessions (POST dosing 
curves) induced by 0.03, 0.1, 0.3, 1, 3, 10, and 20 mg/kg SC naltrexone both pre- and post-
treatement for brain-injured subjects continuously delivered saline (n = 11) or oxycodone 12 
mg/kg/day (n = 11) for 5 days. * significantly different from vehicle p < 0.05. 
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FIGURE 18. Shown are the mean number of food-reinforced lever presses emitted (± standard 
error) during baseline (PRE dosing curves) and precipitated withdrawal sessions (POST dosing 
curves) induced by 0.03, 0.1, 0.3, 1, 3, 10, and 20 mg/kg SC naltrexone both pre- and post-
treatement for sham control subjects continuously delivered saline (n = 7) or oxycodone 12 
mg/kg/day (n = 7) for 5 days. * significantly different from vehicle p < 0.05. 
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FIGURE 19. Shown are the mean withdrawal scores (± standard error) across time both pre- and 
post-pump removal for sham control (n = 8) and brain-injured (n = 10) subjects continuously 
delivered oxycodone 12 mg/kg/day for 10 days. 
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FIGURE 20. Shown are the mean withdrawal scores (± standard error) across time both pre- and 
post-pump removal for sham control (n = 7) and brain-injured (n = 11) subjects continuously 
delivered saline for 10 days. 
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FIGURE 21. Shown are the mean withdrawal scores (± standard error) across time both pre- and 
post-pump removal for sham control and brain-injured subjects continuously delivered saline (n 
= 11) or oxycodone 12 mg/kg/day (n = 10) for 10 days. * significantly different from control p < 
0.05. 
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FIGURE 22. Shown are the mean withdrawal scores (± standard error) across time both pre- and 
post-pump removal for sham control subjects continuously delivered saline (n = 7) or oxycodone 
12 mg/kg/day (n = 8) for 10 days. * significantly different from control p < 0.05. 
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FIGURE 23. Shown are the mean number of food pellets earned (± standard error) across time 
both pre- and post-pump removal for sham control (n = 8) and brain-injured (n = 10) subjects 
continuously delivered oxycodone 12 mg/kg/day for 10 days. 
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FIGURE 24. Shown are the mean number of food pellets earned (± standard error) from 
reinforced lever presses across time both pre- and post-pump removal for both sham control (n = 
7) and brain injured (n = 11) subjects continuously delivered saline for 10 days. * significantly 
different from control p < 0.05. 
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FIGURE 25. Shown are the mean number of food pellets earned (± standard error) from 
reinforced lever presses across time both pre- and post-pump removal for brain-injured subjects 
continuously delivered saline (n = 11) or oxycodone 12 mg/kg/day (n = 10) for 10 days. * 
significantly different from control p < 0.05. 
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FIGURE 26. Shown are the mean number of food pellets earned (± standard error) from 
reinforced lever presses across time both pre- and post-pump removal for sham control subjects 
continuously delivered saline (n = 7) or oxycodone 12 mg/kg/day (n = 8) for 10 days. * 
significantly different from control p < 0.05. 
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FIGURE 27. Shown is the mean distance traveled (± standard error) in the open field across 
time post-pump removal expressed as a percent control of the pre-pump removal baseline both 
sham control and brain-injured subjects continuously delivered saline or oxycodone 12 
mg/kg/day for 10 days. SHAM SAL (n = 14); SHAM OXY (n = 8); INJURED SAL (n = 12); 
INJURED OXY (n = 11). * significant difference between INJURED SAL subjects and 
INJUIRED OXY subjects, p < 0.05; & significant different between SHAM SAL subjects and 
SHAM OXY subjects, p < 0.05. 
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CHAPTER 5: DISCUSSION 
In the first aim, we tested the hypothesis that moderate TBI increases the risk for relapse 
to an opioid use disorder as measured by reinstatement of lever-pressing behavior following 
extinction in an intravenous oxycodone self-administration procedure. Subjects sustaining a 
moderate pressure pulse exhibited damage of central nervous tissue as indicated by elevated 
latencies in the return of the righting reflex, a correlate of injury severity (FIGURE 1) [76–82]. 
Our data, consistent with prior studies, show that oxycodone is an effective reinforcer of lever-
pressing behavior as indicated by preference for the oxycodone-reinforced lever relative to the 
non-reinforced lever (FIGURES 4, 7) [83–86]. In oxycodone-reinforced sessions, brain-injured 
subjects emitted fewer active lever presses after meeting stable maintenance criteria than did non-
injured subjects (FIGURES 4, 7), but showed no significant differences in inactive lever presses 
(FIGURES 5, 8). A possible explanation for the lower level of oxycodone self-administration 
could be differences in the sensitivity to the reinforcing effects of oxycodone following injury. A 
downward or leftward shift in the oxycodone dose-effect curve, a potency shift, may reflect an 
increase in the sensitivity to the reinforcing effects of oxycodone [87–89]. It follows that brain-
injured subjects, relative to non-injured subjects, would require fewer infusions (read: a lower 
cumulative intake) to achieve a comparable hedonic state or to reduce motivation for drug-taking. 
Moreover, changes in sensitivity to the reinforcing effects of a drug of abuse have been correlated 
with relative risk for developing a substance use disorder [90]. Subjects that are more sensitive to 
a drug, require less drug to achieve the desired effect, and subjects less sensitive to the drug, 
administer more drug to achieve the desired effect [90]. Data suggest that subjects that are exposed 
to more drug are more likely to develop a substance use disorder [90]. It follows, then, that brain-
injured subjects may be less likely develop an opioid use disorder. However, further testing must 
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be completed with additional doses of oxycodone and additional schedule parameters to validate 
this hypothesis. 
In non-reinforced extinction tests, brain-injured subjects, relative to non-injured subjects 
showed a trend to require a greater mean number of sessions to meet extinction criteria for lever-
pressing behavior (FIGURE 3). In these tests, all subjects met extinction criteria, but showed no 
significant differences in mean lever presses during extinction sessions across injury condition 
(FIGURE 4). In oxycodone prime-induced reinstatement tests (1 mg/kg, SC), brain-injured and 
non-injured subjects showed decreases in lever-pressing behavior on the active lever, inactive 
lever, and during timeouts relative to lever-pressing behavior during extinction tests (FIGURES 
4–6). A decrease in lever-pressing behavior under these conditions, may represent a non-specific 
depression of behavior due to the sedative effects of oxycodone [91]. When tested for oxycodone 
prime-induced reinstatement at a lower dose (0.3 mg/kg, SC), non-injured subjects showed 
significant increases in lever-pressing behavior relative to lever-pressing behavior during 
extinction sessions (FIGURE 7). Our results, consistent with prior studies, suggest that oxycodone 
priming injection is sufficient to reinstate previously extinguished lever-pressing behavior [37,40]. 
However, brain-injured subjects still failed reinstate to lever-pressing behavior under these 
conditions (FIGURES 4, 7).  
In tests for oxycodone-associated cue-induced reinstatement, non-injured subjects showed 
significant increases in lever-pressing behavior relative to lever-pressing during extinction 
sessions (FIGURE 4). Our results, consistent with prior studies, suggest that exposure to 
oxycodone-associated cues following extinction are sufficient to reinstate lever-pressing behavior 
[38,40,92–95]. In these tests, however, brain-injured subjects, relative to non-injured subjects, 
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showed no changes in lever-pressing behavior on the previously reinforced lever relative to lever-
pressing behavior during extinction tests (FIGURE 4). 
A histological profile of the fluid percussion injury is well-established and indicates that 
neurocircuits which mediate reinstatement to opioid-associated cues and opioid priming injection 
may be disrupted [96–101]. Since injured regions, such as the hippocampus, cortex, and corpus 
callosum, are among the discrete structures involved in these known circuits, it is logical to 
conclude that the reinstatement of behavior following extinction would be affected. It is also 
established that opioid-associated cue and opioid-prime induced reinstatement are blocked by 
temporary, bilateral inactivation of the basolateral amygdala with tetrodotoxin [102]. While the 
histological injury profile suggests that the basolateral amygdala does not sustain damage either 
ipsilateral or contralateral to the site of injury [97] it is known that reciprocal projections between 
the basolateral amygdala, hippocampus, and cortex exist suggesting that disruption of these 
discrete structures, are of importance [57,58,103,104]. It follows, then, that injury to the 
hippocampus and cortex, by proxy of the basolateral amygdala, may be sufficient to attenuate the 
salience of both exteroceptive and interoceptive stimuli [57]. In future studies, assays sensitive to 
changes in the hippocampus, such as a novel object recognition assay or a self-administration 
procedure with a renewal design, may aid in confirming injury to discrete structures involved in 
reinstatement pathways by presence of behavioral disruption [105–111].  
In the second aim, we tested the hypothesis that moderate TBI increases physiological 
dependence to oxycodone as measured by decreases in food-reinforced lever-pressing behavior 
and increases in other withdrawal behaviors in both precipitated withdrawal and spontaneous 
withdrawal. Subjects sustaining a moderate pressure pulse exhibited damage of central nervous 
tissue as indicated by elevated latencies in the return of the righting reflex, a correlate of injury 
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severity (FIGURES 10) [76–82]. In physiological dependence tests, brain-injured subjects, 
relative to non-injured subjects showed no meaningful differences in experimenter assessed 
withdrawal scores or food-reinforced lever-pressing behavior after treatment with continuous 
oxycodone (FIGURES 11, 15). Our results, however, consistent with the results of other studies, 
showed that continuous, non-contingent delivery of oxycodone leads to the development of 
physical dependence for both brain-injured and non-injured subjects as evidenced by increases in 
withdrawal scores (FIGURE 13, 14) and decreases in food-reinforced lever-pressing behavior 
(FIGURE 17, 18) [71–75]. The consistent level of withdrawal across injury condition does not 
support a change in the sensitivity to the effects of oxycodone as suggested by levels of oxycodone 
self-administration in the reinstatement study. An increase in the sensitivity to oxycodone would 
be marked by upward and leftward shifts in the naltrexone dose-effects curves for withdrawal 
scores, and downward and leftward shifts in the curves for food-reinforced lever-pressing 
behavior. However, no meaningful differences in withdrawal scores or food-reinforced lever-
pressing behavior were observed in tests for precipitated withdrawal or spontaneous withdrawal 
in subjects delivered continuous oxycodone. 
In tests for food-reinforced lever-pressing behavior for subjects treated with continuous 
saline, there were significant differences in baseline behavior which complicated the interpretation 
of results. It is possible that this is due to failure to eliminate bias by counterbalancing subjects 
with high baseline lever pressing behavior and low baseline lever pressing behavior across 
treatment groups. However, expression of these data as a percent of vehicle control behavior (data 
not shown) revealed no significant differences in food-reinforced lever pressing behavior across 
the injury condition, except at the highest naltrexone dose tested. Moreover, there were no 
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differences in the mean composite withdrawal scores between brain-injured and non-injured 
subjects, the primary comparison of interest.  
These results indicate that there are no differences in the somatic signs of withdrawal, a 
correlate for the development of physical dependence, between brain-injured subjects and non-
injured subjects. Somatic signs of withdrawal may be mediated by the bed nucleus of the stria 
terminalis, central nucleus of the amygdala, and hypothalamus [57,58,103]. Since the injury profile 
does not indicate damage to either neuroanatomical pathways or discrete structures implicated in 
the production of somatic signs of withdrawal, it follows that differences between brain-injured 
subjects and non-injured subjects would not be expected. Other anatomical substrates mediating 
expression of aversive opioid withdrawal behaviors include the ventral noradrenergic bundle, a 
major source of noradrenergic projections to the bed nucleus of the stria terminalis [112] are not 
believed to be disrupted as a result of the lateral fluid percussion injury [113,114]. Collectively, 
these data may suggest that physical dependence and withdrawal does not contribute to an increase 
in opioid use disorders in TBI patients.  
Overall, the results of this study add to the collective knowledge of our understanding of 
the relationship between brain injury and substance abuse through preclinical models of relapse 
and physical dependence. Our relevant findings are summarized by several principal points. One, 
that brain-injured subjects do not reinstate lever-pressing behavior under oxycodone-associated 
cue or oxycodone prime-induced conditions, suggesting that brain-injured patients, with no 
significant pre-morbid history, are at lesser risk of relapse to opioid abuse. Two, that brain-injured 
subjects are not significantly different from non-injured subjects with regards to their mean 
withdrawal scores or food-reinforced lever-pressing behavior, suggesting that the characteristic 
withdrawal syndrome in opioid-dependent patients does not contribute to continued substance use 
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to greater degree in brain-injured patients versus non-injured patients. Contrary to the 
epidemiological data about the relationship between brain injury and substance abuse, these results 
suggest that brain injury appears to have no impact on oxycodone’s effects and may actually 
decrease the motivation to take drug as well as the risk of relapse.   
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